MOLIQIO: MRD innovation for precision oncology
Ultra-sensitive ctDNA detection for precise cancer monitoring.
IntegraGen, in partnership with Twist Bioscience, offers a solution for liquid biopsy NGS for the detection of ctDNA (LOD : 0,003 %).
Based on personalized panels (WES), an optimized library preparation and a UMI duplex bioinformatics analysis,this approach offers a maximum specificity and a fast turnaround.
CLIA/CAP-compliant, it provides a reliable clinical reporting for the detection of minimal residual disease (MRD) and the therapeutic follow-up oncology patients.
LEARN MORE
👉Fill in the form to access the full Application Note.
👉Ben Sassi et al. Journal of Experimental & Clinical Cancer Research (2025)
👉Watch our Webinar Developing an Integrated MRD Assay to Transform Oncology.
